纳米颗粒治疗多形性胶质母细胞瘤的最新进展。

IF 2.2 4区 医学 Q4 BIOCHEMISTRY & MOLECULAR BIOLOGY
Jugal Mandan, Dr Abhishek Kanugo
{"title":"纳米颗粒治疗多形性胶质母细胞瘤的最新进展。","authors":"Jugal Mandan, Dr Abhishek Kanugo","doi":"10.2174/0113892010352026250213055117","DOIUrl":null,"url":null,"abstract":"<p><p>One of the deadliest and most challenging tumors in the body is Glioblastoma Multiforme (GBM). The Most aggressive kinds of brain tumors pose multiple challenges in their treatment due to several barriers (BBB and BCSF). Conventional treatments show poor efficacy in the treatment owing to poor penetrability through the blood-brain barrier and extreme toxicity in the brain. Moreover, the prognosis and diagnosis of GBM are critical, as they can lead to a fatal outcome.The current state-of-the-art review emphasizes the novel theranostic nanoparticles, which are significantly effective in treating the GBM. The most effective nanocarriers are lipid-based (Liposomes, Solid lipid nanoparticles, nanostructured lipid carrier, nanoemulsion), polymeric (polymeric micelles, dendrimers, quantum dots, exosomes, and hydrogels), metallic (Gold, Silver, Platinum), inorganic (iron oxide, mesoporous silica, copper oxide, boron oxide, Gadolinium, Selenium, and Zinc oxide NPs), carbon-based (Carbon nanotubes and graphene oxide) and others (protein-based NPs, Cubosomes, Polymersosomes). These nanoparticle-loaded antitumor agents show good penetration across the barriers and improve survival rates compared to conventional ones. Lipid-based nanoparticles are preferred for providing high biocompatibility, biodegradability, and sustained release action. Polymeric nanocarriers are preferred for facilitating long-acting therapy, and patient comfort, mostly for their biosensing features. Carbon-based nanomaterials are gaining interest for their theranostic action. The most promising outcomes in clinical practices are shown in Liposomes, PLGAbased NPs, Gold NPs, hydrogels, iron oxide NPs, albumin-based NPs, etc.</p>","PeriodicalId":10881,"journal":{"name":"Current pharmaceutical biotechnology","volume":" ","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2025-03-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Recent Advancements in Nanoparticles-Based Approaches for the Theranostics of Glioblastoma Multiforme.\",\"authors\":\"Jugal Mandan, Dr Abhishek Kanugo\",\"doi\":\"10.2174/0113892010352026250213055117\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>One of the deadliest and most challenging tumors in the body is Glioblastoma Multiforme (GBM). The Most aggressive kinds of brain tumors pose multiple challenges in their treatment due to several barriers (BBB and BCSF). Conventional treatments show poor efficacy in the treatment owing to poor penetrability through the blood-brain barrier and extreme toxicity in the brain. Moreover, the prognosis and diagnosis of GBM are critical, as they can lead to a fatal outcome.The current state-of-the-art review emphasizes the novel theranostic nanoparticles, which are significantly effective in treating the GBM. The most effective nanocarriers are lipid-based (Liposomes, Solid lipid nanoparticles, nanostructured lipid carrier, nanoemulsion), polymeric (polymeric micelles, dendrimers, quantum dots, exosomes, and hydrogels), metallic (Gold, Silver, Platinum), inorganic (iron oxide, mesoporous silica, copper oxide, boron oxide, Gadolinium, Selenium, and Zinc oxide NPs), carbon-based (Carbon nanotubes and graphene oxide) and others (protein-based NPs, Cubosomes, Polymersosomes). These nanoparticle-loaded antitumor agents show good penetration across the barriers and improve survival rates compared to conventional ones. Lipid-based nanoparticles are preferred for providing high biocompatibility, biodegradability, and sustained release action. Polymeric nanocarriers are preferred for facilitating long-acting therapy, and patient comfort, mostly for their biosensing features. Carbon-based nanomaterials are gaining interest for their theranostic action. The most promising outcomes in clinical practices are shown in Liposomes, PLGAbased NPs, Gold NPs, hydrogels, iron oxide NPs, albumin-based NPs, etc.</p>\",\"PeriodicalId\":10881,\"journal\":{\"name\":\"Current pharmaceutical biotechnology\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":2.2000,\"publicationDate\":\"2025-03-18\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current pharmaceutical biotechnology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.2174/0113892010352026250213055117\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q4\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current pharmaceutical biotechnology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.2174/0113892010352026250213055117","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0

摘要

多形性胶质母细胞瘤(GBM)是人体最致命和最具挑战性的肿瘤之一。由于脑屏障(血脑屏障和脑脊液)的存在,最具侵袭性的脑肿瘤在治疗中面临多重挑战。常规治疗方法由于血脑屏障渗透性差和脑毒性大,治疗效果不佳。此外,GBM的预后和诊断是至关重要的,因为它们可能导致致命的结果。目前最先进的回顾强调了新型治疗纳米颗粒,它在治疗GBM方面显着有效。最有效的纳米载体是脂质基(脂质体、固体脂质纳米颗粒、纳米结构脂质载体、纳米乳液)、聚合物(聚合物胶束、树突、量子点、外泌体和水凝胶)、金属(金、银、铂)、无机(氧化铁、介孔二氧化硅、氧化铜、氧化硼、钆、硒和氧化锌)、碳基(碳纳米管和氧化石墨烯)和其他(蛋白质基纳米粒、立方体体、聚合体)。与传统的抗肿瘤药物相比,这些纳米颗粒负载的抗肿瘤药物表现出良好的穿透屏障和提高生存率。脂基纳米颗粒具有较高的生物相容性、可生物降解性和缓释作用。高分子纳米载体是促进长效治疗和患者舒适的首选,主要是因为它们的生物传感特性。碳基纳米材料因其治疗作用而引起人们的兴趣。在临床实践中最有希望的结果是脂质体、基于plgaba的NPs、金NPs、水凝胶、氧化铁NPs、白蛋白NPs等。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Recent Advancements in Nanoparticles-Based Approaches for the Theranostics of Glioblastoma Multiforme.

One of the deadliest and most challenging tumors in the body is Glioblastoma Multiforme (GBM). The Most aggressive kinds of brain tumors pose multiple challenges in their treatment due to several barriers (BBB and BCSF). Conventional treatments show poor efficacy in the treatment owing to poor penetrability through the blood-brain barrier and extreme toxicity in the brain. Moreover, the prognosis and diagnosis of GBM are critical, as they can lead to a fatal outcome.The current state-of-the-art review emphasizes the novel theranostic nanoparticles, which are significantly effective in treating the GBM. The most effective nanocarriers are lipid-based (Liposomes, Solid lipid nanoparticles, nanostructured lipid carrier, nanoemulsion), polymeric (polymeric micelles, dendrimers, quantum dots, exosomes, and hydrogels), metallic (Gold, Silver, Platinum), inorganic (iron oxide, mesoporous silica, copper oxide, boron oxide, Gadolinium, Selenium, and Zinc oxide NPs), carbon-based (Carbon nanotubes and graphene oxide) and others (protein-based NPs, Cubosomes, Polymersosomes). These nanoparticle-loaded antitumor agents show good penetration across the barriers and improve survival rates compared to conventional ones. Lipid-based nanoparticles are preferred for providing high biocompatibility, biodegradability, and sustained release action. Polymeric nanocarriers are preferred for facilitating long-acting therapy, and patient comfort, mostly for their biosensing features. Carbon-based nanomaterials are gaining interest for their theranostic action. The most promising outcomes in clinical practices are shown in Liposomes, PLGAbased NPs, Gold NPs, hydrogels, iron oxide NPs, albumin-based NPs, etc.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Current pharmaceutical biotechnology
Current pharmaceutical biotechnology 医学-生化与分子生物学
CiteScore
5.60
自引率
3.60%
发文量
203
审稿时长
6 months
期刊介绍: Current Pharmaceutical Biotechnology aims to cover all the latest and outstanding developments in Pharmaceutical Biotechnology. Each issue of the journal includes timely in-depth reviews, original research articles and letters written by leaders in the field, covering a range of current topics in scientific areas of Pharmaceutical Biotechnology. Invited and unsolicited review articles are welcome. The journal encourages contributions describing research at the interface of drug discovery and pharmacological applications, involving in vitro investigations and pre-clinical or clinical studies. Scientific areas within the scope of the journal include pharmaceutical chemistry, biochemistry and genetics, molecular and cellular biology, and polymer and materials sciences as they relate to pharmaceutical science and biotechnology. In addition, the journal also considers comprehensive studies and research advances pertaining food chemistry with pharmaceutical implication. Areas of interest include: DNA/protein engineering and processing Synthetic biotechnology Omics (genomics, proteomics, metabolomics and systems biology) Therapeutic biotechnology (gene therapy, peptide inhibitors, enzymes) Drug delivery and targeting Nanobiotechnology Molecular pharmaceutics and molecular pharmacology Analytical biotechnology (biosensing, advanced technology for detection of bioanalytes) Pharmacokinetics and pharmacodynamics Applied Microbiology Bioinformatics (computational biopharmaceutics and modeling) Environmental biotechnology Regenerative medicine (stem cells, tissue engineering and biomaterials) Translational immunology (cell therapies, antibody engineering, xenotransplantation) Industrial bioprocesses for drug production and development Biosafety Biotech ethics Special Issues devoted to crucial topics, providing the latest comprehensive information on cutting-edge areas of research and technological advances, are welcome. Current Pharmaceutical Biotechnology is an essential journal for academic, clinical, government and pharmaceutical scientists who wish to be kept informed and up-to-date with the latest and most important developments.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信